ArticlePLoS pathogens2008
VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis.
Article in PLoS pathogens, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Proteomics of plasma-derived extracellular vesicles from human patients identifies biomarkers for monitoring visceral leishmaniasis therapy.Frontiers in immunology · 2025Article
- A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases.JCI insight · 2023Article
- Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.Clinical and translational science · 2022Article
- B Cell Adhesion to Fibroblast-Like Synoviocytes Is Up-Regulated by Tumor Necrosis Factor-Alpha via Expression of Human Vascular Cell Adhesion Molecule-1 Mediated by B Cell-Activating Factor.International journal of molecular sciences · 2021Article
- Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.Frontiers in immunology · 2021Review
- Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment.Frontiers in pharmacology · 2020Article
- Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.The Journal of infectious diseases · 2019Article
- IL-4 Mediated Resistance of BALB/c Mice to Visceral Leishmaniasis Is Independent of IL-4Rα Signaling via T Cells.Frontiers in immunology · 2019Article
- Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1.Cellular oncology (Dordrecht, Netherlands) · 2017Review
- VCAM-1 and ICAM-1 Serum Levels as Markers of Relapse in Visceral Leishmaniasis.Mediterranean journal of hematology and infectious diseases · 2017Article
- Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.PLoS neglected tropical diseases · 2016Article
- Dendritic Cells and Leishmania Infection: Adding Layers of Complexity to a Complex Disease.Journal of immunology research · 2016Review
- Article
- Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells.International journal of molecular sciences · 2014Article
- Mapping the genes for susceptibility and response to Leishmania tropica in mouse.PLoS neglected tropical diseases · 2013Article
- Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection.PLoS pathogens · 2011Article
- Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.Antioxidants & redox signaling · 2011Review
- Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity.Infection and immunity · 2011Article
- High parasite burdens cause liver damage in mice following Plasmodium berghei ANKA infection independently of CD8(+) T cell-mediated immune pathology.Infection and immunity · 2011Article
- Isoforms of vitamin E differentially regulate inflammation.Endocrine, metabolic & immune disorders drug targets · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Vascular cell adhesion molecule-1 (VCAM-1) interacts with its major ligand very late antigen-4 (VLA-4) to mediate cell adhesion and transendothelial migration of leukocytes. We report an important role for VCAM-1/VLA-4 interactions in the generation of immune responses during experimental visceral leishmaniasis caused by Leishmania donovani. Our studies demonstrate that these molecules play no direct role in the recruitment of leukocytes to the infected liver, but instead contribute to IL-12p40-production by splenic CD8(+) dendritic cells (DC). Blockade of VCAM-1/VLA-4 interactions using whole antibody or anti-VCAM-1 Fab' fragments reduced IL-12p40 mRNA accumulation by splenic DC 5 hours after L. donovani infection. This was associated with reduced anti-parasitic CD4(+) T cell activation in the spleen and lowered hepatic IFNgamma, TNF and nitric oxide production by 14 days post infection. Importantly, these effects were associated with enhanced parasite growth in the liver in studies with either anti-VCAM-1 or anti-VLA-4 antibodies. These data indicate a role for VCAM-1 and VLA-4 in DC activation during infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.